ViOptix Inc.

ViOptix Inc. is a medical technology company specializing in intraoperative monitoring solutions that enhance surgical outcomes through real-time tissue oxygenation data, improving decision-making for clinicians during procedures. Founded in 1999 and headquartered in Fremont, US, ViOptix Inc. provides advanced medical technology solutions.

The company has successfully pivoted its business strategy, focusing on innovative monitoring systems. The CEO, Scott Coleridge, leads the company which has raised USD 2. 93 mn in its latest funding round, Series D, from investors including 5Y Capital, Channel Medical Partners, and Vivo Capital, bringing the total amount raised to USD 2. 93 mn with a current valuation of USD 30.

112 mn. ViOptix specializes in advanced medical technology, focusing on their core product offerings, T. Ox and Intra. Ox, designed for intraoperative monitoring of tissue oxygenation.

These technologies provide real-time data to clinicians, enabling informed decisions during surgical procedures and enhancing patient outcomes. The T. Ox system, including Remote and Intra variants, has been implemented in leading hospitals across the United States, Canada, and several European countries. Key users of these products are healthcare professionals, particularly surgeons and anesthesiologists, who rely on accurate tissue oxygenation readings to optimize surgical interventions.

ViOptix generates revenue through direct sales of its monitoring systems and support services to healthcare facilities. The company engages in B2B transactions, with hospitals and surgical centers purchasing the T. Ox and Intra. Ox systems, complemented by ongoing support and training services.

The pricing structure accommodates the varying needs of institutional clients, based on unit volume and service contract extent, making ViOptix’s offerings integral to the success of healthcare providers focused on improving surgical outcomes. In December 2008, ViOptix Inc. raised USD 2. 93 mn in Series D venture funding, valuing the company at USD 30.

112 mn post-money, which will be utilized for the development of new products and expansion into additional geographic markets. The company aims to enhance its product lines and reach out to healthcare markets across new regions, specifically targeting growth opportunities in Europe and Asia by 2025.